TECH — Bio-Techne Corporation

The market is pricing a high probability that the Merck KGaA acquisition closes, not expressing bullishness on organic fundamentals: as of 2026-08-27 the stock was $72.47 versus the $73.00 cash buyout. FY2026 revenue was flat at $1.22B, adjusted EPS was roughly flat at $1.93, and Bio-Techne has suspended guidance and earnings calls due to the pending deal. Analyst ratings are split (12 buy / 14 hold / 0 sell), with a consensus rating of Hold and targets clustered between the $65.78 consensus and the $73 deal cap, reflecting uncertainty between close and no-close scenarios.

Revenue over the last 12 quarters has been roughly flat: FY2024 revenue was $1.159B, FY2025 was $1.220B, and FY2026 was $1.215B. Q4 FY2026 revenue of $321.2M was the strongest quarter and up ~1.3% YoY, but the prior three FY2026 quarters were all roughly flat-to-slightly-down YoY, so this is stabilization/digestion, not a growth re-acceleration. The profit trend is cleaner: TTM operating margin improved to 20.7% from 17.8% in FY2024, and TTM GAAP EPS rose to $1.16 from $0.46, helped by the absence of the one-off -$23.9M operating loss recorded in Q4 FY2025. The fundamental read is a high-quality life-sciences tools business in a low-growth cyclical trough, with margins and cash flow intact rather than a business in structural decline.

At $72.47 as of 2026-08-27, TECH trades at 61.9x TTM GAAP EPS, 9.3x TTM sales, and 5.4x book value. Against its own 5-year averages of 66.4x P/E and 9.8x P/S, that is roughly neutral versus history, not cheap. The forward P/E on next-FY consensus EPS of $2.055 is about 35x, which is rich but consistent with the high-margin franchise and the pending cash offer. The 0.40 PEG is misleading because the trailing EPS base is distorted by the FY2025 one-off loss, so it should be ignored. At the deal price, Merck pays about 37.8x FY2026 adjusted EPS of $1.93, and the analyst target range of $50-$73 shows how much value depends on deal completion.

Investors are not paying 35x forward earnings for future growth here; they are paying a 0.7% discount to $73.00 cash. If the deal closes, the earnings multiple is irrelevant and the payout is fixed. If the deal fails, the stock likely re-rates to a standalone multiple around 28-30x next-FY EPS of $2.055, or roughly $58-$62, implying the current price embeds a mid-90s% market-implied deal-close probability. This is a spread trade, not a growth-vs-estimates stock-picking situation.

As of 2026-08-27, RSI was 68.68, just below overbought, and the stock was +0.32% above its 20-day SMA, +3.15% above its 50-day SMA, and +19.55% above its 200-day SMA. The stock has been trending up since the June 25, 2026 acquisition announcement and sits near its 52-week high of $72.62, but the chart is a reflection of merger convergence, not organic demand. For entry timing, the technical picture indicates no meaningful upside left—the effective ceiling is the $73.00 takeover price.

• Life-sciences tools capex cycle: biopharma clients remain cautious on instrument purchases and lab expansions, keeping Bio-Techne's organic growth near zero.
• Cross-border M&A regulation: the Merck KGaA acquisition requires antitrust and foreign-investment clearances; any delay or veto would hit the stock hard.
• Biotech funding and interest rates: academic and biotech customer budgets are sensitive to grant availability and financing costs, which have been a demand drag.
• Event overhang: the September 23, 2026 shareholder vote and a $230.5M termination-fee structure make the deal calendar the dominant macro factor.
• Currency: reported international revenue can swing on FX, though the $73.00 per-share cash consideration is fixed in dollars.

• Shareholder vote on September 23, 2026 to approve the $73.00/share Merck KGaA acquisition.
• Receipt of antitrust/foreign-investment regulatory approvals and closing of the transaction in late 2026/early 2027.
• Compression of the remaining ~$0.53 spread as the market becomes more confident in the closing date.
• If the deal terminates, potential strategic alternatives or a higher bid could reprice the stock; the termination fee would provide only partial downside cushion.

• Deal failure: if shareholders or regulators reject the Merck transaction, shares could fall to a standalone value near $58-$62, a double-digit percentage downside from $72.47.
• Unfavorable arbitrage: the spread is only ~$0.53, so new buyers bear deal-completion and time risk for less than 1% upside.
• Fundamental stagnation: if the deal is delayed or terminated, flat revenue, cautious biopharma spending, and suspended guidance leave no near-term growth catalyst.
• Interim-period disruption: talent retention, customer contracts, and operational momentum could erode while the company operates under the pending acquisition.

Today TECH is best understood as a short-dated cash takeover: Merck KGaA has agreed to pay $73.00 per share, and the stock is $0.53 below that. The business itself is high-quality—20.7% TTM operating margin, ~$263M TTM free cash flow, and a low-debt balance sheet—but organic growth is flat and the deal has already been priced in. For a new investor, the expected return is small relative to event risk; for existing shareholders, the sensible framework is essentially a cash-out at $73 unless there is a specific view that the deal breaks.

I used a probability-weighted merger value: approximately 96.5% probability of receiving the $73.00 Merck cash consideration and 3.5% probability the deal fails, with a standalone fallback of ~$61.65 (30x next-FY consensus EPS of $2.055). That gives 0.965 * $73.00 + 0.035 * $61.65 = $72.60 as the theoretical fair value as of 2026-08-27, independent of the analyst consensus target.